| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8453500 | Leukemia Research Reports | 2018 | 4 Pages |
Abstract
We retrospectively analyzed twenty-six patients with primary plasma cell leukemia (pPCL) registered from May 2005 until April 2015 by the Kansai Myeloma Forum. Twenty patients received novel agents (bortezomib or lenalidomide), and their median survival of was 34 months. The median survival of patients who underwent autologous stem cell transplantation (SCT) was 40 months, those undergoing allogeneic SCT 55 months, and those undergoing both types of SCT (auto-allo) 61 months; whereas for those who did not undergo SCT it was 28 months (pâ¯=â¯0.845). The only statistically significant risk factor identified by multivariate analysis was hypercalcemia.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Aya Nakaya, Hideo Yagi, Hitomi Kaneko, Satoru Kosugi, Toru Kida, Yoko Adachi, Hirohiko Shibayama, Takae Kohara, Yuri Kamitsuji, Shin-ichi Fuchida, Nobuhiko Uoshima, Eri Kawata, Hitoji Uchiyama, Yuji Shimura, Takayuki Takahashi, Fumiaki Urase,